Table 1.
Ref. | Country | CIMP-H CRCs/tested CRCs n (%) |
|
In all CRCs | In MSI-H CRCs | ||
Western countries | |||
Samowitz et al[22], 2005 | United States | 250/859 (29.1) | 64/78 (82.1) |
Weisenberger et al[13], 2006 | United States | 33/187 (17.6) | NA |
Samowitz et al[84], 2006 | United States | 313/1271 (24.6) | 105/170 (61.8) |
Barault et al[85], 2008 | France | 95/578 (16.4) | 58/80 (72.5) |
Ogino et al[4], 2009 | United States | 123/631 (19.5) | 86/118 (72.9) |
Dahlin et al[86], 2010 | Sweden | 46/411 (11.2) | 34/61 (55.7) |
Zlobec et al[24], 2011 | Switzerland | 22/314 (7) | NA |
Lochhead et al[63], 2013 | United States | 205/1173 (17.5) | 140/184 (76.1) |
Eastern countries | |||
Koinuma et al[101], 2004 | Japan | NA | 161/28 (57.1) |
Nagasaka et al[102], 2008 | Japan and Germany | NA | 152/36 (41.7) |
Kim et al[98], 2009 | South Korea | 29/271 (10.7) | 8/33 (24.2) |
Min et al[99], 2011 | South Korea | 34/245 (13.9) | NA |
Bae et al[97], 2013 | South Korea | 47/734 (6.4) | 18/65 (27.7) |
Kim et al[25], 2013 | South Korea | NA | 64/220 (29.1) |
MLH1-methylated colorectal cancers (CRCs) instead of CpG island methylator phenotype-high (CIMP-H) CRCs;
Sporadic microsatellite instability-high (MSI-H) CRCs instead of CIMP-H CRCs. NA: Not applicable.